BIOGEN INC.
Biological Products, (No Diagnostic Substances) · 225 BINNEY STREET, CAMBRIDGE, MA 02142
官方登记数据
0位关注者
1978成立于
关于 BIOGEN INC.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
Source: Wikipedia
行业Biological Products, (No Diagnostic Substances)
总部225 BINNEY STREET, CAMBRIDGE, MA 02142
成立1978
法律形式C Corporation
状态营业中
专利34 项专利
THERAPEUTIC AND DIAGNOSTIC METHODS FOR MULTIPLE SCLEROSISWO2024015331A1 · 2024
PROCESS FOR PREPARING SPIRO DERIVATIVES.MX2020003821A · 2023
关键数据
法律信息
| 法定名称 | BIOGEN INC. |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 875045在 SEC EDGAR 上查看 ↗ |
| EIN | 33-0112644 |
| 行业代码(SIC) | 2836 |
| 注册地址 | 225 BINNEY STREET, CAMBRIDGE, MA 02142 |
| 状态 | 营业中 |
来源: SEC EDGAR · 更新于 Oct. 15, 2026